首页 > 最新文献

Critical Pathways in Cardiology最新文献

英文 中文
Transcatheter Aortic Valve Implantation in Brazilian Public Health System: A Single-Center Experience. 经导管主动脉瓣植入在巴西公共卫生系统:单一中心的经验。
Q3 Medicine Pub Date : 2025-06-01 Epub Date: 2025-05-23 DOI: 10.1097/HPC.0000000000000387
Guilherme Pinheiro Machado, Pedro Castilhos Crivelaro, Gustavo Neves de Araujo, Alan Pagnoncelli, Julia Carvalho da Silva, Camila Porto Cardoso, Wagner Tadeu Azeredo Azevedo, Rodrigo Petersen Saadi, Eduardo Keller Saadi, Orlando Wender, Marco Wainstein, Felipe Costa Fuchs

Background: Transcatheter aortic valve implantation (TAVI) has been established as the treatment of choice for severe aortic stenosis in high-risk patients as well as patients above 75 years old in all risk spectrums. Despite its worldwide adoption, implementation in lower-middle-income countries such as the Brazilian public health system (SUS, acronym in Portuguese) is incipient.

Objectives: This study aimed to evaluate TAVI exclusively within SUS patients.

Methods: This was a prospective cohort study in a public tertiary hospital in southern Brazil. All patients who underwent TAVI between 2018 and 2024 were included. The cohort was divided into 2 temporal periods: from July 2018 to December 2022 (n = 60) and January 2023 to October 2024 (n = 65). The clinical and procedural characteristics and in-hospital, as well as 1 year of outcomes, were evaluated according to Valve Academic Research Consortium-2 (VARC-2) criteria.

Results: During the study period, 125 patients underwent TAVI. The average age was 80 years (± 10), and 49.6% were male. The mean aortic valve area was 0.76 cm² and the mean gradient was 45 (±13) mm Hg. The mean STS predicted risk of mortality (STS-PROM) score was 4.6% (±3.6). Device success was achieved in 119 patients (95.2%). In-hospital mortality was 2 (1.6%). A new permanent pacemaker was required in 16 (12.8%). Demographic and clinical characteristics between the first and the second periods were similar.

Conclusions: The mortality and complications rate of TAVI performed within the scope of the Brazilian public health system were consistent with the clinical experience of other international registries.

背景:经导管主动脉瓣植入术(TAVI)已被确定为治疗重度主动脉瓣狭窄的高危人群以及75岁以上所有危险谱患者的首选方法。尽管它在世界范围内被采用,但在巴西公共卫生系统(SUS,葡萄牙语首字母缩略词)等中低收入国家的实施才刚刚开始。目的:本研究旨在专门评估SUS患者的TAVI。方法:在巴西南部一家公立三级医院进行前瞻性队列研究。所有在2018年至2024年间接受TAVI的患者都被纳入其中。该队列被分为两个时间段:2018年7月至2022年12月(n=60)和2023年1月至2024年10月(n=65)。根据瓣膜学术研究联盟-2 (VARC-2)标准评估临床和手术特征、住院和1年预后。结果:在研究期间,125例患者接受了TAVI。平均年龄80岁(±10岁),男性占49.6%。平均主动脉瓣面积为0.76 cm2,平均梯度为45(±13)mmHg。STS预测死亡风险(STS- prom)平均评分为4.6%(±3.6)。119例患者(95.2%)器械成功。住院死亡率为2(1.6%)。16例(12.8%)需要新的永久性起搏器。第一期和第二期的人口学和临床特征相似。结论:在巴西公共卫生系统范围内进行TAVI的死亡率和并发症发生率与其他国际登记的临床经验一致。
{"title":"Transcatheter Aortic Valve Implantation in Brazilian Public Health System: A Single-Center Experience.","authors":"Guilherme Pinheiro Machado, Pedro Castilhos Crivelaro, Gustavo Neves de Araujo, Alan Pagnoncelli, Julia Carvalho da Silva, Camila Porto Cardoso, Wagner Tadeu Azeredo Azevedo, Rodrigo Petersen Saadi, Eduardo Keller Saadi, Orlando Wender, Marco Wainstein, Felipe Costa Fuchs","doi":"10.1097/HPC.0000000000000387","DOIUrl":"10.1097/HPC.0000000000000387","url":null,"abstract":"<p><strong>Background: </strong>Transcatheter aortic valve implantation (TAVI) has been established as the treatment of choice for severe aortic stenosis in high-risk patients as well as patients above 75 years old in all risk spectrums. Despite its worldwide adoption, implementation in lower-middle-income countries such as the Brazilian public health system (SUS, acronym in Portuguese) is incipient.</p><p><strong>Objectives: </strong>This study aimed to evaluate TAVI exclusively within SUS patients.</p><p><strong>Methods: </strong>This was a prospective cohort study in a public tertiary hospital in southern Brazil. All patients who underwent TAVI between 2018 and 2024 were included. The cohort was divided into 2 temporal periods: from July 2018 to December 2022 (n = 60) and January 2023 to October 2024 (n = 65). The clinical and procedural characteristics and in-hospital, as well as 1 year of outcomes, were evaluated according to Valve Academic Research Consortium-2 (VARC-2) criteria.</p><p><strong>Results: </strong>During the study period, 125 patients underwent TAVI. The average age was 80 years (± 10), and 49.6% were male. The mean aortic valve area was 0.76 cm² and the mean gradient was 45 (±13) mm Hg. The mean STS predicted risk of mortality (STS-PROM) score was 4.6% (±3.6). Device success was achieved in 119 patients (95.2%). In-hospital mortality was 2 (1.6%). A new permanent pacemaker was required in 16 (12.8%). Demographic and clinical characteristics between the first and the second periods were similar.</p><p><strong>Conclusions: </strong>The mortality and complications rate of TAVI performed within the scope of the Brazilian public health system were consistent with the clinical experience of other international registries.</p>","PeriodicalId":35914,"journal":{"name":"Critical Pathways in Cardiology","volume":" ","pages":"e0387"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Altered Anthropometrics and HbA1c Levels, but not Dyslipidemia, Are Associated With Elevated hs-CRP Levels in Middle-aged Adults: A Population-based Analysis. 人体测量学和 HA1c 水平的改变(而非血脂异常)与中年人 hs-CRP 水平的升高有关:基于人群的分析。
Q3 Medicine Pub Date : 2025-06-01 Epub Date: 2025-05-23 DOI: 10.1097/HPC.0000000000000378
Laith Ashour, Layan Ayesh, Zeid Jarrar, Areen Mishleb, Danah Alenezi, Moath Fateh, Rawan Almejaibal, Nicola Hanna Madani, Muath Mohammad Dabas, Sama Samer Abu Monshar, Samar Hamdan

Population-based studies of cardiovascular disease markers, such as high-sensitivity C-reactive protein (hs-CRP), are crucial. However, studies exploring the effect of metabolic indices on hs-CRP while controlling for confounding variables adequately in middle-aged adults are limited. Using Wave 5 public-use biomarkers data from the National Longitudinal Study of Adolescent to Adult Health (Add Health), we examined the impact of various metabolic indices on hs-CRP in adults aged 32-42, controlling for eight allergic and infectious factors that may elevate hs-CRP levels. We used multiple linear regression analysis to determine which factors predict hs-CRP levels after the log transformation of the dependent variable. The total number of participants was N = 1839 (weighted N = 1,390,763), with a mean age of 38.1 (SD = 2.0) and 46.4% having obesity. Among the controlled variables, recent surgery was the only confounder to significantly predict increased hs-CRP levels [ P = 0.029; exponentiated estimate (EE) = 1.61; 95% confidence interval (Cl), 1.31-1.91]. Notably, current smoking and altered low-density lipoprotein levels did not show a significant association with hs-CRP levels ( P > 0.05). However, a significant increase in hs-CRP levels was observed in females compared with males ( P < 0.001; EE = 1.43; 95% Cl, 1.35-1.51). Similar findings were noted for diabetic HbA1c levels ( P = 0.001; EE = 1.6; 95% CI, 1.42-1.78), high waist circumference ( P = 0.015; EE = 1.25; 95% CI, 1.15-1.35), and stage 3 obesity ( P = 0.006; EE = 7.62; 95% CI, 2.86-12.38). Although not statistically significant, hs-CRP levels exhibited a gradual increase with rising body mass index after controlling for other variables. These findings will improve the clinical application of hs-CRP in predicting coronary artery disease, especially in younger adults.

对心血管疾病标志物(如 hs-CRP)进行基于人群的研究至关重要。然而,在充分控制中年人混杂变量的情况下,探讨代谢指数对 hs-CRP 影响的研究非常有限。利用全国青少年健康纵向研究(Add Health)的第 5 波数据,我们研究了各种代谢指数对 32-42 岁成年人的 hs-CRP 的影响,同时控制了可能导致 hs-CRP 水平升高的八种过敏和感染因素。我们使用多元线性回归分析来确定哪些因素可以预测因变量对数变换后的 hs-CRP 水平。参与者总数为 N = 1839(加权 N = 1390763),平均年龄为 38.1 岁(SD = 2.0),46.4% 患有肥胖症。在控制变量中,近期手术是唯一能显著预测 hs-CRP 水平升高的混杂因素(P = 0.029,指数估计值 (EE) = 1.61;95% Cl:[1.31-1.91]).值得注意的是,目前吸烟和低密度脂蛋白或总胆固醇水平的改变与 hs-CRP 水平没有显著关联(P > 0.05)。然而,与男性相比,女性的 hs-CRP 水平明显升高(P < 0.001,EE = 1.43;95%Cl:[1.35-1.51])。糖尿病 HbA1c 水平(P = 0.001,EE = 1.6;95%CL:[1.42-1.78])、高腰围(P = 0.015,EE = 1.25;95%CL:[1.15-1.35])和 3 级肥胖(P = 0.006,EE = 7.62;95%CL:[2.86-12.38])也有类似发现。尽管没有统计学意义,但在控制了其他变量后,hs-CRP水平随着体重指数的升高而逐渐增加。这些发现将提高 hs-CRP 在预测冠状动脉疾病方面的临床应用,尤其是在年轻人中。
{"title":"Altered Anthropometrics and HbA1c Levels, but not Dyslipidemia, Are Associated With Elevated hs-CRP Levels in Middle-aged Adults: A Population-based Analysis.","authors":"Laith Ashour, Layan Ayesh, Zeid Jarrar, Areen Mishleb, Danah Alenezi, Moath Fateh, Rawan Almejaibal, Nicola Hanna Madani, Muath Mohammad Dabas, Sama Samer Abu Monshar, Samar Hamdan","doi":"10.1097/HPC.0000000000000378","DOIUrl":"10.1097/HPC.0000000000000378","url":null,"abstract":"<p><p>Population-based studies of cardiovascular disease markers, such as high-sensitivity C-reactive protein (hs-CRP), are crucial. However, studies exploring the effect of metabolic indices on hs-CRP while controlling for confounding variables adequately in middle-aged adults are limited. Using Wave 5 public-use biomarkers data from the National Longitudinal Study of Adolescent to Adult Health (Add Health), we examined the impact of various metabolic indices on hs-CRP in adults aged 32-42, controlling for eight allergic and infectious factors that may elevate hs-CRP levels. We used multiple linear regression analysis to determine which factors predict hs-CRP levels after the log transformation of the dependent variable. The total number of participants was N = 1839 (weighted N = 1,390,763), with a mean age of 38.1 (SD = 2.0) and 46.4% having obesity. Among the controlled variables, recent surgery was the only confounder to significantly predict increased hs-CRP levels [ P = 0.029; exponentiated estimate (EE) = 1.61; 95% confidence interval (Cl), 1.31-1.91]. Notably, current smoking and altered low-density lipoprotein levels did not show a significant association with hs-CRP levels ( P > 0.05). However, a significant increase in hs-CRP levels was observed in females compared with males ( P < 0.001; EE = 1.43; 95% Cl, 1.35-1.51). Similar findings were noted for diabetic HbA1c levels ( P = 0.001; EE = 1.6; 95% CI, 1.42-1.78), high waist circumference ( P = 0.015; EE = 1.25; 95% CI, 1.15-1.35), and stage 3 obesity ( P = 0.006; EE = 7.62; 95% CI, 2.86-12.38). Although not statistically significant, hs-CRP levels exhibited a gradual increase with rising body mass index after controlling for other variables. These findings will improve the clinical application of hs-CRP in predicting coronary artery disease, especially in younger adults.</p>","PeriodicalId":35914,"journal":{"name":"Critical Pathways in Cardiology","volume":" ","pages":"e0378"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142476566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of the Presence of Interatrial Block as a Prediction Pathway of Atrial Fibrillation During the Postoperative Period of Patients Undergoing Cardiac Surgery. 心房传导阻滞作为心脏手术患者术后房颤预测途径的作用
Q3 Medicine Pub Date : 2025-06-01 Epub Date: 2025-05-23 DOI: 10.1097/HPC.0000000000000384
Alfredo J Meza-Delgado, Osmar Antonio Centurión, Christian O Chavez-Alfonso, Rocío Del Pilar Falcón-Fleytas, Laura B García-Bello, Orlando R Sequeira-Villar, Carmen R Montiel-Gómez, José C Candia-Irala, Erdulfo J Galeano

Background: Atrial fibrillation (AF) is the most frequently recorded arrhythmia in clinical practice, and its appearance conditions high risk of morbidity and mortality. The role of the interatrial block (IAB) as a predictor pathway of the development of AF in the postoperative period of patients undergoing cardiac surgery has been studied scantly.

Methods: Partial IAB was defined as the P wave >120 ms and advanced IAB as the P wave >120 ms with biphasic morphology in inferior leads. The presurgical electrocardiography was analyzed, and the frequency of AF onset in the postoperative period was determined. A comparative analysis was performed between the patients who presented AF and those who did not.

Results: A total of 94 patients were included, with a mean age of 61 ± 16 years. Of the total number of patients, 42 (45%) presented some degree of IAB (partial 42.8% and advanced 57.1%). There was a significant relationship between patients with IAB and those who developed AF postcardiac surgery (21.3%; P < 0.01). The presence of IAB had an area under the curve of 0.75 (95% confidence interval, 0.66-0.85) and demonstrated a specificity of 69%, a sensitivity of 83%, and a negative predictive value of 92% for predicting AF development.

Conclusions: IAB has a relatively frequent incidence in patients undergoing cardiac surgery. There was a significant association between the presence of IAB and the development of AF in the postoperative period. Our findings establish for the first time that IAB has high specificity, sensitivity, and negative predictive value for predicting AF development postcardiac surgery.

背景:心房颤动(AF)是临床上最常见的心律失常,其出现会导致高发病率和高死亡率。心房间阻滞(IAB)是心脏手术患者术后发生房颤的预测途径,但对其作用的研究却很少:部分IAB定义为P波>120毫秒,晚期IAB定义为P波>120毫秒且下导联呈双相形态。对手术前的心电图进行分析,并确定术后房颤发生的频率。对出现房颤和未出现房颤的患者进行了对比分析:共纳入 94 例患者,平均年龄为 61±16 岁。在所有患者中,42 人(45%)患有某种程度的 IAB(部分 42.8%,晚期 57.1%)。IAB患者与心脏手术后出现房颤的患者(21.3%)之间存在明显关系:IAB在接受心脏手术的患者中发病率较高。IAB的存在与术后房颤的发生有明显的关联。我们的研究结果首次证实,IAB 对预测心脏手术后房颤的发生具有很高的特异性、敏感性和阴性预测价值。
{"title":"Role of the Presence of Interatrial Block as a Prediction Pathway of Atrial Fibrillation During the Postoperative Period of Patients Undergoing Cardiac Surgery.","authors":"Alfredo J Meza-Delgado, Osmar Antonio Centurión, Christian O Chavez-Alfonso, Rocío Del Pilar Falcón-Fleytas, Laura B García-Bello, Orlando R Sequeira-Villar, Carmen R Montiel-Gómez, José C Candia-Irala, Erdulfo J Galeano","doi":"10.1097/HPC.0000000000000384","DOIUrl":"10.1097/HPC.0000000000000384","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) is the most frequently recorded arrhythmia in clinical practice, and its appearance conditions high risk of morbidity and mortality. The role of the interatrial block (IAB) as a predictor pathway of the development of AF in the postoperative period of patients undergoing cardiac surgery has been studied scantly.</p><p><strong>Methods: </strong>Partial IAB was defined as the P wave >120 ms and advanced IAB as the P wave >120 ms with biphasic morphology in inferior leads. The presurgical electrocardiography was analyzed, and the frequency of AF onset in the postoperative period was determined. A comparative analysis was performed between the patients who presented AF and those who did not.</p><p><strong>Results: </strong>A total of 94 patients were included, with a mean age of 61 ± 16 years. Of the total number of patients, 42 (45%) presented some degree of IAB (partial 42.8% and advanced 57.1%). There was a significant relationship between patients with IAB and those who developed AF postcardiac surgery (21.3%; P < 0.01). The presence of IAB had an area under the curve of 0.75 (95% confidence interval, 0.66-0.85) and demonstrated a specificity of 69%, a sensitivity of 83%, and a negative predictive value of 92% for predicting AF development.</p><p><strong>Conclusions: </strong>IAB has a relatively frequent incidence in patients undergoing cardiac surgery. There was a significant association between the presence of IAB and the development of AF in the postoperative period. Our findings establish for the first time that IAB has high specificity, sensitivity, and negative predictive value for predicting AF development postcardiac surgery.</p>","PeriodicalId":35914,"journal":{"name":"Critical Pathways in Cardiology","volume":" ","pages":"e0384"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Access to Nonphysician Led Exercise Stress Echocardiography Reduces Wait Times and Improves Consumer Engagement. 非医生引导的运动压力超声心动图减少了等待时间,提高了消费者的参与度。
Q3 Medicine Pub Date : 2025-06-01 Epub Date: 2025-05-23 DOI: 10.1097/HPC.0000000000000379
Mark Whitman, Carly Jenkins, Prasad Challa

The performance of nonphysician-led exercise stress testing with and without echocardiography has shown similar diagnostic utility and safety as physician-led models. While diagnostic accuracy and relative safety have been the focus of previous research, the current study aims to demonstrate efficiencies not previously reported, such as reduction in wait times for testing and improved service attendance. A nonphysician-led exercise stress echocardiography service was implemented on January 01, 2018; before this, all tests were performed under a physician-led model. Retrospective data was retrieved from both models (physician-led model from January 01, 2015 to December 31, 2017 and the nonphysician-led model from January 01, 2018 to December 31, 2023). Comparisons were made between the models regarding the number of tests performed, the average wait time to access testing, and the did not attend (DNA) rates. On average, 212 tests were performed in the physician-led model per year, with average wait times to access testing of 11.3 weeks and a DNA rate of 15.3%. In contrast, the nonphysician-led model performed on average 501 tests per year (135% increase) ( P < 0.001) with average wait times of 6 weeks (47% decrease) ( P < 0.01) and DNA rate of 4.8% (69% decrease). Despite the physician-led group displaying an overall higher cardiovascular disease risk, there were no adverse cardiovascular events at the time of testing in either model. Nonphysician-led exercise stress echocardiography remains as safe as physician-led models but demonstrates service improvements, including significant reductions in wait times and lower DNA rates.

有和没有超声心动图的非医生领导的运动压力测试显示出与医生领导的模型相似的诊断效用和安全性。虽然诊断的准确性和相对安全性一直是先前研究的重点,但目前的研究旨在证明以前未报道的效率,例如减少等待检测的时间和提高服务出勤率。非医生主导的运动应激超声心动图(ESE)服务于2018年1月1日实施,在此之前,所有测试都是在医生主导的模式下进行的。从两个模型中检索回顾性数据(2015年1月1日至2017年12月31日由医生领导的模型和2018年1月1日至2023年12月31日由非医生领导的模型)。在模型之间进行了关于执行的测试次数、获得测试的平均等待时间和未参加(DNA)率的比较。在医生主导的模式下,每年平均进行212次检测,平均等待时间为11.3周,DNA率为15.3%。相比之下,非医生主导的模型平均每年进行501次测试(增加135%)
{"title":"Access to Nonphysician Led Exercise Stress Echocardiography Reduces Wait Times and Improves Consumer Engagement.","authors":"Mark Whitman, Carly Jenkins, Prasad Challa","doi":"10.1097/HPC.0000000000000379","DOIUrl":"10.1097/HPC.0000000000000379","url":null,"abstract":"<p><p>The performance of nonphysician-led exercise stress testing with and without echocardiography has shown similar diagnostic utility and safety as physician-led models. While diagnostic accuracy and relative safety have been the focus of previous research, the current study aims to demonstrate efficiencies not previously reported, such as reduction in wait times for testing and improved service attendance. A nonphysician-led exercise stress echocardiography service was implemented on January 01, 2018; before this, all tests were performed under a physician-led model. Retrospective data was retrieved from both models (physician-led model from January 01, 2015 to December 31, 2017 and the nonphysician-led model from January 01, 2018 to December 31, 2023). Comparisons were made between the models regarding the number of tests performed, the average wait time to access testing, and the did not attend (DNA) rates. On average, 212 tests were performed in the physician-led model per year, with average wait times to access testing of 11.3 weeks and a DNA rate of 15.3%. In contrast, the nonphysician-led model performed on average 501 tests per year (135% increase) ( P < 0.001) with average wait times of 6 weeks (47% decrease) ( P < 0.01) and DNA rate of 4.8% (69% decrease). Despite the physician-led group displaying an overall higher cardiovascular disease risk, there were no adverse cardiovascular events at the time of testing in either model. Nonphysician-led exercise stress echocardiography remains as safe as physician-led models but demonstrates service improvements, including significant reductions in wait times and lower DNA rates.</p>","PeriodicalId":35914,"journal":{"name":"Critical Pathways in Cardiology","volume":" ","pages":"e0379"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Temporal Trends and Outcomes of Peripheral Artery Disease and Critical Limb Ischemia in the United States. 美国外周动脉疾病和严重肢体缺血的时间趋势和结果。
Q3 Medicine Pub Date : 2025-06-01 Epub Date: 2025-05-23 DOI: 10.1097/HPC.0000000000000377
Chayakrit Krittanawong, Kimberly Imoh, Song Peng Ang, Yusuf Kamran Qadeer, Hafeez Ul Hassan Virk, Mahboob Alam, Carl J Lavie, Raman Sharma

Introduction: Peripheral artery disease (PAD) is a progressive, systemic atherosclerotic disease that is associated with an increased risk of coronary artery disease, cerebrovascular disease, and critical limb ischemia (CLI). CLI represents the most severe stage of PAD, characterized by progressive endothelial dysfunction and arterial narrowing. We hypothesized that the incidence of CLI and PAD would increase over the study period and that the rates of in-hospital mortality and major amputations among patients admitted with CLI would rise correspondingly.

Methods: We utilized the National Inpatient Sample database from 2016 to 2021 using the International Classification of Disease, Tenth Edition, Clinical Modification codes. Patients with primary or secondary diagnoses of PAD were initially selected, and subsequently hospitalization with CLI was appropriately identified. The Cochran Armitage test was used to describe the trend of outcomes across the years. All statistical analyses were conducted using the software Stata version 17.0.

Results: From 2016 to 2021, there were 2,930,639 admissions for CLI. Up to 65% of these patients were over the age of 60, and 35.8% of these patients were women. Most of these individuals were white (64.7%), followed by African Americans (15.8%) and Hispanics (12.6%). In-hospital mortality rates varied by revascularization method, with hybrid revascularization showing the highest rate at 2.6%, followed by endovascular revascularization at 1.8%, and surgical revascularization at 1.6%. Additionally, hospitalization costs were highest for patients undergoing hybrid revascularization ($46,257 ± $36,417), compared with endovascular ($36,924 ± $27,945) and surgical revascularization ($35,672 ± $27,127). Endovascular revascularization rates seemed to increase while surgical revascularization rates decreased during this time period.

Conclusions: PAD is a progressive, systemic atherosclerotic disease that is associated with an increased risk of coronary artery disease, cerebrovascular disease, and CLI. Our data showed that the rates of PAD and CLI hospitalizations have remained relatively stable from 2016 to 2021, but there seems to be a trend toward doing more revascularization via an endovascular approach as compared to a surgical approach.

简介:外周动脉疾病(PAD)是一种进行性、全身性动脉粥样硬化疾病,与冠状动脉疾病(CAD)、脑血管疾病(CVD)和严重肢体缺血(CLI)的风险增加有关。临界肢体缺血是 PAD 最严重的阶段,其特点是进行性内皮功能障碍和动脉狭窄。我们假设,在研究期间,CLI 和 PAD 的发病率会增加,CLI 患者的院内死亡率和主要截肢率也会相应增加:我们利用 2016 年至 2021 年的全国住院患者抽样(NIS)数据库,使用 ICD-10-CM 编码。我们首先选择了主要或次要诊断为 PAD 的患者,然后对 CLI 住院患者进行了适当识别。Cochran Armitage 检验用于描述不同年份的结果趋势。所有统计分析均使用Stata 17.0版软件进行:2016-2021年,共有2,930,639人因严重肢体缺血入院治疗。其中 65% 的患者年龄在 60 岁以上,35.8% 的患者为女性。其中大部分是白人(64.7%),其次是非裔美国人(15.8%)和西班牙裔美国人(12.6%)。院内死亡率因血管再通方法而异,其中混合血管再通的死亡率最高,为 2.6%,其次是血管内再通术,为 1.8%,手术血管再通术为 1.6%。此外,接受杂交血管再造术的患者住院费用最高(46257美元±36417美元),而接受血管内再造术(36924美元±27945美元)和外科再造术(35672美元±27127美元)的患者住院费用最低。在此期间,血管内再通率似乎有所上升,而手术再通率则有所下降:结论:PAD 是一种进行性、全身性动脉粥样硬化疾病,与 CAD、CVD 和 CLI 风险增加有关。我们的数据显示,PAD 和 CLI 住院率在 2016-2021 年间保持相对稳定,但与手术方法相比,似乎有通过血管内方法进行血管重建的趋势。
{"title":"Temporal Trends and Outcomes of Peripheral Artery Disease and Critical Limb Ischemia in the United States.","authors":"Chayakrit Krittanawong, Kimberly Imoh, Song Peng Ang, Yusuf Kamran Qadeer, Hafeez Ul Hassan Virk, Mahboob Alam, Carl J Lavie, Raman Sharma","doi":"10.1097/HPC.0000000000000377","DOIUrl":"10.1097/HPC.0000000000000377","url":null,"abstract":"<p><strong>Introduction: </strong>Peripheral artery disease (PAD) is a progressive, systemic atherosclerotic disease that is associated with an increased risk of coronary artery disease, cerebrovascular disease, and critical limb ischemia (CLI). CLI represents the most severe stage of PAD, characterized by progressive endothelial dysfunction and arterial narrowing. We hypothesized that the incidence of CLI and PAD would increase over the study period and that the rates of in-hospital mortality and major amputations among patients admitted with CLI would rise correspondingly.</p><p><strong>Methods: </strong>We utilized the National Inpatient Sample database from 2016 to 2021 using the International Classification of Disease, Tenth Edition, Clinical Modification codes. Patients with primary or secondary diagnoses of PAD were initially selected, and subsequently hospitalization with CLI was appropriately identified. The Cochran Armitage test was used to describe the trend of outcomes across the years. All statistical analyses were conducted using the software Stata version 17.0.</p><p><strong>Results: </strong>From 2016 to 2021, there were 2,930,639 admissions for CLI. Up to 65% of these patients were over the age of 60, and 35.8% of these patients were women. Most of these individuals were white (64.7%), followed by African Americans (15.8%) and Hispanics (12.6%). In-hospital mortality rates varied by revascularization method, with hybrid revascularization showing the highest rate at 2.6%, followed by endovascular revascularization at 1.8%, and surgical revascularization at 1.6%. Additionally, hospitalization costs were highest for patients undergoing hybrid revascularization ($46,257 ± $36,417), compared with endovascular ($36,924 ± $27,945) and surgical revascularization ($35,672 ± $27,127). Endovascular revascularization rates seemed to increase while surgical revascularization rates decreased during this time period.</p><p><strong>Conclusions: </strong>PAD is a progressive, systemic atherosclerotic disease that is associated with an increased risk of coronary artery disease, cerebrovascular disease, and CLI. Our data showed that the rates of PAD and CLI hospitalizations have remained relatively stable from 2016 to 2021, but there seems to be a trend toward doing more revascularization via an endovascular approach as compared to a surgical approach.</p>","PeriodicalId":35914,"journal":{"name":"Critical Pathways in Cardiology","volume":" ","pages":"e0377"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142355630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) Trial. 在急诊科启动高脂血症的预防性护理:EMERALD(急诊医学心血管疾病风险评估)试验。
Q3 Medicine Pub Date : 2025-04-22 DOI: 10.1097/HPC.0000000000000390
Nicklaus P Ashburn, Anna C Snavely, Molly R Ehrig, Michael D Shapiro, David M Herrington, David M Reboussin, Sabina B Gesell, Simon A Mahler

Background: Hyperlipidemia (HLD) is a major contributor to atherosclerotic cardiovascular disease (ASCVD). Nearly 30% of Emergency Department (ED) patients with chest pain have undiagnosed and/or unmanaged HLD, putting them at an increased risk of ASCVD. Although safe and effective HLD treatments exist, the ED traditionally focuses on acute care and does not offer preventive cardiovascular care services. This represents a large, missed opportunity to improve cardiovascular health for the millions of Americans evaluated in the ED each year who are not receiving appropriate preventive care in the outpatient setting. The goals of this study are to determine the efficacy of novel ED-initiated preventive care on lowering cholesterol while also informing our understanding of patient adherence and implementation determinants of ED-initiated preventive cardiovascular care.

Methods: We will use a randomized, controlled, parallel group trial of 130 ED patients being evaluated for acute coronary syndrome (ACS) at a single site. Participants will be 40-75 years old with prior ASCVD, known diabetes, or 10-year ASCVD risk ≥7.5% who are not already receiving guideline-directed outpatient preventive care. Patients will be randomized with equal probability to EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) or usual care. Patients in the EMERALD arm will be started on a statin and referred for 30-day follow-up with cardiology or primary care, depending on 10-year ASCVD risk level. Usual care arm patients will not be prescribed a statin in the ED and will be asked to follow-up with a primary care provider. The primary outcome will be percent change in low-density lipoprotein cholesterol (LDL-C) at 30-days. Secondary outcomes include percent change in LDL-C at 180-days and non-high-density lipoprotein cholesterol (non-HDL-C) at 30- and 180-days, the proportion of EMERALD patients who pick up their statin, and the proportion of patients who attend 30-day outpatient follow-up. We will also use mixed methods and semi-structured interviews to identify patient adherence facilitators and barriers as well as implementation determinants for Emergency Medicine providers.

Discussion: This is the first study to evaluate a novel, protocolized ED-initiated preventive cardiovascular care approach for HLD. If successful, the EMERALD intervention may be able to improve the cardiovascular health for at-risk patients and serve as a use case for other modifiable cardiovascular disease risk factors, such as diabetes, hypertension, tobacco use, and obesity. This single site study will inform a planned multisite trial.

背景:高脂血症(HLD)是动脉粥样硬化性心血管疾病(ASCVD)的主要诱因。近30%的急诊科(ED)胸痛患者患有未确诊和/或未治疗的HLD,这使他们患ASCVD的风险增加。虽然存在安全有效的HLD治疗方法,但ED传统上侧重于急性护理,而不提供预防性心血管护理服务。这代表了一个巨大的,错过了改善心血管健康的机会,因为每年在急诊室评估的数百万美国人没有在门诊环境中接受适当的预防保健。本研究的目的是确定新型ed发起的预防保健对降低胆固醇的功效,同时也告知我们对ed发起的心血管预防保健的患者依从性和实施决定因素的理解。方法:我们将采用一项随机、对照、平行组试验,在单一地点评估130例ED患者的急性冠脉综合征(ACS)。参与者年龄40-75岁,既往ASCVD,已知糖尿病,或10年ASCVD风险≥7.5%,尚未接受指南指导的门诊预防护理。患者将以等概率随机分配到EMERALD(急诊医学心血管风险评估脂质紊乱)或常规护理组。EMERALD组的患者将开始使用他汀类药物,并根据10年ASCVD风险水平进行为期30天的心脏病学或初级保健随访。常规护理组的患者不会在急诊科开他汀类药物,并将被要求与初级保健提供者进行随访。主要终点是30天低密度脂蛋白胆固醇(LDL-C)的百分比变化。次要结局包括180天LDL-C和30天和180天非高密度脂蛋白胆固醇(non-HDL-C)的百分比变化,接受他汀类药物治疗的EMERALD患者比例,以及参加30天门诊随访的患者比例。我们还将使用混合方法和半结构化访谈来确定患者依从性的促进因素和障碍,以及急诊医学提供者的实施决定因素。讨论:这是第一个评估一种新的、程序化ed启动的HLD预防性心血管护理方法的研究。如果成功,EMERALD干预可能能够改善高危患者的心血管健康,并可作为其他可改变的心血管疾病风险因素(如糖尿病、高血压、吸烟和肥胖)的用例。这项单点研究将为计划中的多点试验提供信息。
{"title":"Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) Trial.","authors":"Nicklaus P Ashburn, Anna C Snavely, Molly R Ehrig, Michael D Shapiro, David M Herrington, David M Reboussin, Sabina B Gesell, Simon A Mahler","doi":"10.1097/HPC.0000000000000390","DOIUrl":"10.1097/HPC.0000000000000390","url":null,"abstract":"<p><strong>Background: </strong>Hyperlipidemia (HLD) is a major contributor to atherosclerotic cardiovascular disease (ASCVD). Nearly 30% of Emergency Department (ED) patients with chest pain have undiagnosed and/or unmanaged HLD, putting them at an increased risk of ASCVD. Although safe and effective HLD treatments exist, the ED traditionally focuses on acute care and does not offer preventive cardiovascular care services. This represents a large, missed opportunity to improve cardiovascular health for the millions of Americans evaluated in the ED each year who are not receiving appropriate preventive care in the outpatient setting. The goals of this study are to determine the efficacy of novel ED-initiated preventive care on lowering cholesterol while also informing our understanding of patient adherence and implementation determinants of ED-initiated preventive cardiovascular care.</p><p><strong>Methods: </strong>We will use a randomized, controlled, parallel group trial of 130 ED patients being evaluated for acute coronary syndrome (ACS) at a single site. Participants will be 40-75 years old with prior ASCVD, known diabetes, or 10-year ASCVD risk ≥7.5% who are not already receiving guideline-directed outpatient preventive care. Patients will be randomized with equal probability to EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) or usual care. Patients in the EMERALD arm will be started on a statin and referred for 30-day follow-up with cardiology or primary care, depending on 10-year ASCVD risk level. Usual care arm patients will not be prescribed a statin in the ED and will be asked to follow-up with a primary care provider. The primary outcome will be percent change in low-density lipoprotein cholesterol (LDL-C) at 30-days. Secondary outcomes include percent change in LDL-C at 180-days and non-high-density lipoprotein cholesterol (non-HDL-C) at 30- and 180-days, the proportion of EMERALD patients who pick up their statin, and the proportion of patients who attend 30-day outpatient follow-up. We will also use mixed methods and semi-structured interviews to identify patient adherence facilitators and barriers as well as implementation determinants for Emergency Medicine providers.</p><p><strong>Discussion: </strong>This is the first study to evaluate a novel, protocolized ED-initiated preventive cardiovascular care approach for HLD. If successful, the EMERALD intervention may be able to improve the cardiovascular health for at-risk patients and serve as a use case for other modifiable cardiovascular disease risk factors, such as diabetes, hypertension, tobacco use, and obesity. This single site study will inform a planned multisite trial.</p>","PeriodicalId":35914,"journal":{"name":"Critical Pathways in Cardiology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12353110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coronary Perforation Occurring During Percutaneous Coronary Intervention Is Associated With Persistently High Mortality and Complications. 在经皮冠状动脉介入治疗过程中发生的冠状动脉穿孔与居高不下的死亡率和并发症有关。
Q3 Medicine Pub Date : 2025-03-01 Epub Date: 2025-02-21 DOI: 10.1097/HPC.0000000000000373
Mohammad Reza Movahed, Nishant Satapathy, Mehrtash Hashemzadeh

Introduction: Coronary perforation is one of the major complications of percutaneous coronary intervention (PCI). The goal of this study was to evaluate adverse outcomes and mortality in patients suffering from coronary perforation during PCI above the age of 30.

Methods: The National Inpatient Sample database, years 2016-2020, was studied using International Classification of Diseases, Tenth Revision codes. Patients suffering from perforation were compared with patients without perforation during PCI.

Results: PCI was performed in a weighted total of 10,059,269 patients. Coronary perforation occurred in 11,725 (0.12%) of all PCI performed. The mortality rate of patients with perforations was very high in comparison to patients without perforations. (12.9% vs. 2.5%, odds ratio, 5.6; CI, 5-6.3; P < 0.001). Furthermore, patients with coronary perforations had much higher rates of urgent coronary bypass surgery, tamponade, cardiac arrest, and major cardiovascular outcomes. Mortality remained high and over 10% in the 5-year study period.

Conclusions: Using a large national inpatient database, all-cause inpatient mortality in patients with coronary perforation is very high (over 10%), with persistently high mortality rates over the years, suggesting that treatment of perforations needs further improvement.

简介:冠状动脉穿孔是经皮冠状动脉介入治疗(PCI)的主要并发症之一。本研究旨在评估 30 岁以上在经皮冠状动脉介入治疗过程中发生冠状动脉穿孔的患者的不良预后和死亡率:使用 ICD 10 代码对 2016-2020 年全国住院患者样本(NIS)数据库进行研究。将PCI过程中发生穿孔的患者与未发生穿孔的患者进行比较:加权后共有 10,059,269 名患者接受了 PCI 治疗。在所有实施 PCI 的患者中,有 11,725 例(0.12%)发生了冠状动脉穿孔。与未发生穿孔的患者相比,发生穿孔的患者死亡率非常高。(12.9% vs 2.5%,OR:5.6,CI:5-6.3):通过使用大型全国住院患者数据库,冠状动脉穿孔患者的全因住院死亡率非常高(超过 10%),而且多年来死亡率一直居高不下,这表明穿孔的治疗需要进一步改进。
{"title":"Coronary Perforation Occurring During Percutaneous Coronary Intervention Is Associated With Persistently High Mortality and Complications.","authors":"Mohammad Reza Movahed, Nishant Satapathy, Mehrtash Hashemzadeh","doi":"10.1097/HPC.0000000000000373","DOIUrl":"10.1097/HPC.0000000000000373","url":null,"abstract":"<p><strong>Introduction: </strong>Coronary perforation is one of the major complications of percutaneous coronary intervention (PCI). The goal of this study was to evaluate adverse outcomes and mortality in patients suffering from coronary perforation during PCI above the age of 30.</p><p><strong>Methods: </strong>The National Inpatient Sample database, years 2016-2020, was studied using International Classification of Diseases, Tenth Revision codes. Patients suffering from perforation were compared with patients without perforation during PCI.</p><p><strong>Results: </strong>PCI was performed in a weighted total of 10,059,269 patients. Coronary perforation occurred in 11,725 (0.12%) of all PCI performed. The mortality rate of patients with perforations was very high in comparison to patients without perforations. (12.9% vs. 2.5%, odds ratio, 5.6; CI, 5-6.3; P < 0.001). Furthermore, patients with coronary perforations had much higher rates of urgent coronary bypass surgery, tamponade, cardiac arrest, and major cardiovascular outcomes. Mortality remained high and over 10% in the 5-year study period.</p><p><strong>Conclusions: </strong>Using a large national inpatient database, all-cause inpatient mortality in patients with coronary perforation is very high (over 10%), with persistently high mortality rates over the years, suggesting that treatment of perforations needs further improvement.</p>","PeriodicalId":35914,"journal":{"name":"Critical Pathways in Cardiology","volume":" ","pages":"e0373"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141627941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Single Long Stents Versus Overlapping Stents on Clinical Outcomes in Primary PCI. 单个长支架与重叠支架对初次PCI临床结果的影响。
Q3 Medicine Pub Date : 2025-03-01 Epub Date: 2025-02-21 DOI: 10.1097/HPC.0000000000000371
Guilherme Pinheiro Machado, Martin Negreira-Caamaño, Daniel Tébar Márquez, Marcia Moura Schmidt, Alan Pagnoncelli, Gustavo Neves de Araujo, Sandro Cadaval Goncalves, Marco Wainstein, Alexandre Schaan de Quadros, Alfonso Jurado-Román, Rodrigo Wainstein

Background: Patients with long coronary lesions undergoing primary percutaneous coronary intervention (pPCI) have higher rates of adverse clinical events. Both stent length and stent overlap are associated with worse outcomes; however, data comparing very long stent (VLS) to overlapping stents (OSs) are limited, particularly during pPCI. This study aimed to compare the impact of a single VLS versus ≥2 OSs on clinical outcomes in a multicenter registry of patients undergoing pPCI.

Methods: This study included patients with ST-segment elevation myocardial infarction (STEMI) who underwent pPCI using a single VLS (≥38 mm) or ≥2 OS (total stent length, ≥38 mm) in the culprit lesion. After propensity score matching based on tortuosity, calcification, Killip class, culprit lesion length ≥40 mm, and culprit vessel, the final cohort for analysis was selected. The primary endpoint was a combination of mortality and target lesion failure (reinfarction, stent thrombosis, or new revascularization) at 2 years.

Results: Among 647 consecutive STEMI patients who underwent pPCI between March 2016 and September 2022, 353 received VLS and 294 received OSs. After propensity score matching, 264 patients remained (132 in each group). The occurrence of the primary outcome (VLS: 12.9 vs. OS: 15.9%; P = 0.86), all-cause mortality (VLS: 7.6 vs. OS: 9.8%; P = 0.51), and target lesion failure (VLS: 8.3 vs. OS: 6.8, P = 0.64) were similar between the 2 groups.

Conclusions: In this cohort of real-world patients with STEMI undergoing pPCI, we found no significant difference in outcomes between VLS and OSs. Both strategies are reasonable treatment options for STEMI patients.

背景:接受pPCI的冠状动脉长病变患者有较高的不良临床事件发生率。支架长度和支架重叠与较差的预后相关;然而,比较VLS和OS的数据是有限的,特别是在pPCI期间。本研究旨在比较单个超长支架(VLS)与≥2个重叠支架(OS)对接受原发性经皮冠状动脉介入治疗(pPCI)患者临床结果的影响。方法:本研究纳入st段抬高型心肌梗死(STEMI)患者,这些患者接受了首次PCI治疗,在罪魁祸首病变中使用单个VLS(≥38 mm)或≥2个OS(总支架长度≥38 mm)。根据扭曲度、钙化、Killip分级、罪魁祸首病变长度≥40 mm和罪魁祸首血管进行倾向评分匹配(PSM)后,选择最终队列进行分析。主要终点是2年时的死亡率和靶病变失败(TLF)(再梗死、支架血栓形成或新的血运重建)。结果:在2016年3月至2022年9月期间,647例连续接受pPCI的STEMI患者中,353例接受了VLS, 294例接受了OS。PSM后,264例患者(每组132例)。主要结局(VLS:12.9 vs. OS:15.9%, p=0.86)、全因死亡率(VLS:7.6)。vs OS:9.8%, p=0.51),靶病变失败(VLS: 8.3 vs OS: 6.8, p=0.64)两组之间相似。结论:在这个接受pPCI的STEMI患者队列中,我们发现VLS和OS之间的结果没有显著差异。这两种策略都是STEMI患者的合理治疗选择。
{"title":"Impact of Single Long Stents Versus Overlapping Stents on Clinical Outcomes in Primary PCI.","authors":"Guilherme Pinheiro Machado, Martin Negreira-Caamaño, Daniel Tébar Márquez, Marcia Moura Schmidt, Alan Pagnoncelli, Gustavo Neves de Araujo, Sandro Cadaval Goncalves, Marco Wainstein, Alexandre Schaan de Quadros, Alfonso Jurado-Román, Rodrigo Wainstein","doi":"10.1097/HPC.0000000000000371","DOIUrl":"10.1097/HPC.0000000000000371","url":null,"abstract":"<p><strong>Background: </strong>Patients with long coronary lesions undergoing primary percutaneous coronary intervention (pPCI) have higher rates of adverse clinical events. Both stent length and stent overlap are associated with worse outcomes; however, data comparing very long stent (VLS) to overlapping stents (OSs) are limited, particularly during pPCI. This study aimed to compare the impact of a single VLS versus ≥2 OSs on clinical outcomes in a multicenter registry of patients undergoing pPCI.</p><p><strong>Methods: </strong>This study included patients with ST-segment elevation myocardial infarction (STEMI) who underwent pPCI using a single VLS (≥38 mm) or ≥2 OS (total stent length, ≥38 mm) in the culprit lesion. After propensity score matching based on tortuosity, calcification, Killip class, culprit lesion length ≥40 mm, and culprit vessel, the final cohort for analysis was selected. The primary endpoint was a combination of mortality and target lesion failure (reinfarction, stent thrombosis, or new revascularization) at 2 years.</p><p><strong>Results: </strong>Among 647 consecutive STEMI patients who underwent pPCI between March 2016 and September 2022, 353 received VLS and 294 received OSs. After propensity score matching, 264 patients remained (132 in each group). The occurrence of the primary outcome (VLS: 12.9 vs. OS: 15.9%; P = 0.86), all-cause mortality (VLS: 7.6 vs. OS: 9.8%; P = 0.51), and target lesion failure (VLS: 8.3 vs. OS: 6.8, P = 0.64) were similar between the 2 groups.</p><p><strong>Conclusions: </strong>In this cohort of real-world patients with STEMI undergoing pPCI, we found no significant difference in outcomes between VLS and OSs. Both strategies are reasonable treatment options for STEMI patients.</p>","PeriodicalId":35914,"journal":{"name":"Critical Pathways in Cardiology","volume":" ","pages":"e0371"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of a High Sensitivity Troponin HEART Pathway-Based Clinical Decision Protocol on Observation Visits. 基于高灵敏度肌钙蛋白 HEART 途径的临床决策规程对观察访问的影响。
Q3 Medicine Pub Date : 2025-03-01 Epub Date: 2025-02-21 DOI: 10.1097/HPC.0000000000000370
George B Hughes, Iyesatta Emeli, Matthew A Wheatley, Abhinav Goyal, Janetta Bryksin, Timothy P Moran, Matthew T Keadey, Michael A Ross

Background: Use of high-sensitivity troponin (hs-cTn) might lead to an increase in hospital observation visits due to a higher number of abnormal troponin levels.

Study objectives: To determine the impact of incorporating hs-cTn into a chest pain clinical decision protocol (CDP) on observation visits in a large academic health system.

Methods: This is a retrospective observational cohort study of all chest pain observation patients in 4 hospitals in an academic health system over 24 months. All hospitals used the Beckman Coulter Unicel Dxi instrument, and all shared the same emergency department (ED) chest pain protocol, which used the HEART pathway and serial troponins and directed ED dispositions to either an observation stay, ED discharge, or inpatient admission. Outcomes studied before and after the introduction of an hs-cTn protocol included daily chest pain observation census, cost, observation hours, and inpatient admit rate. Census was reported as the daily chest pain observation census and as a proportion of all observation visits. Data were retrieved from a health system data warehouse and a cost accounting program.

Results: There were 6712 chest pain observation visits over 24 months, with 4087 visits before and 2634 visits after the hs-cTn protocol implementation. Comparison groups were similar in terms of age, gender, and type of insurance. There were 10.59 (95% CI, 10.24-10.95) daily chest pain observation visits before and 7.66 (95% CI, 7.34-7.97) visits after implementation, with a 28% (95% CI, 35%-20%) decrease in the total daily census. As a portion of all observation visits, there was a 22% drop in the proportion that were observed for chest pain. The daily number of chest pain patients requiring inpatient admission was unchanged. The daily total direct cost for chest pain observation decreased with an effective daily cost savings of $4313 USD (95% CI, $1534-$6998). The total daily number of chest pain observation bed hours also decreased by 41.5 hours (95% CI, 13.4-96.4 hours).

Conclusions: Implementation of a hs-cTn chest pain protocol was associated with a significant decrease in the number and proportion of observation visits, a decrease in total daily cost and bed hours used, and no increase in inpatient admissions.

研究背景使用高敏肌钙蛋白(hs-cTn)可能会因肌钙蛋白水平异常次数增多而导致住院观察次数增加:方法:这是一项回顾性观察队列研究:这是一项回顾性观察性队列研究,研究对象是学术医疗系统中四家医院 24 个月内的所有胸痛观察患者。所有医院都使用了贝克曼库尔特 Unicel Dxi 仪器,并且都采用了相同的急诊科(ED)胸痛治疗方案,该方案使用 HEART 路径和连续肌钙蛋白,并将急诊科的处置定向为留院观察、急诊科出院或住院。采用 hs-cTn 方案前后的研究结果包括每日胸痛观察人数、费用、观察时间和住院率。观察人数以每日胸痛观察人数和占所有观察就诊人数的比例进行报告。数据取自医疗系统数据仓库和成本核算程序:在 24 个月的时间里,共有 6712 人次接受了胸痛观察,其中 4087 人次是在实施 hs-cTn 方案之前,2634 人次是在实施该方案之后。对比组的年龄、性别和保险类型相似。实施前的每日胸痛观察人次为 10.59(95% CI:10.24 - 10.95)次,实施后为 7.66(95% CI:7.34 - 7.97)次,每日总人次减少了 28%(95% CI:35% - 20%)。在所有观察次数中,因胸痛而接受观察的比例下降了 22%。每天需要住院治疗的胸痛患者人数保持不变。胸痛观察的每日直接费用总额有所下降,每日有效节省费用 4313 美元(95% CI:1534 - 6998 美元)。每日胸痛观察床时总数也减少了 41.5 小时(95% CI 13.4 - 96.4 小时):结论:实施 hs-cTn 胸痛方案可显著减少观察就诊的次数和比例,降低每日总费用和所用床时,并且不会增加住院人数。
{"title":"The Impact of a High Sensitivity Troponin HEART Pathway-Based Clinical Decision Protocol on Observation Visits.","authors":"George B Hughes, Iyesatta Emeli, Matthew A Wheatley, Abhinav Goyal, Janetta Bryksin, Timothy P Moran, Matthew T Keadey, Michael A Ross","doi":"10.1097/HPC.0000000000000370","DOIUrl":"10.1097/HPC.0000000000000370","url":null,"abstract":"<p><strong>Background: </strong>Use of high-sensitivity troponin (hs-cTn) might lead to an increase in hospital observation visits due to a higher number of abnormal troponin levels.</p><p><strong>Study objectives: </strong>To determine the impact of incorporating hs-cTn into a chest pain clinical decision protocol (CDP) on observation visits in a large academic health system.</p><p><strong>Methods: </strong>This is a retrospective observational cohort study of all chest pain observation patients in 4 hospitals in an academic health system over 24 months. All hospitals used the Beckman Coulter Unicel Dxi instrument, and all shared the same emergency department (ED) chest pain protocol, which used the HEART pathway and serial troponins and directed ED dispositions to either an observation stay, ED discharge, or inpatient admission. Outcomes studied before and after the introduction of an hs-cTn protocol included daily chest pain observation census, cost, observation hours, and inpatient admit rate. Census was reported as the daily chest pain observation census and as a proportion of all observation visits. Data were retrieved from a health system data warehouse and a cost accounting program.</p><p><strong>Results: </strong>There were 6712 chest pain observation visits over 24 months, with 4087 visits before and 2634 visits after the hs-cTn protocol implementation. Comparison groups were similar in terms of age, gender, and type of insurance. There were 10.59 (95% CI, 10.24-10.95) daily chest pain observation visits before and 7.66 (95% CI, 7.34-7.97) visits after implementation, with a 28% (95% CI, 35%-20%) decrease in the total daily census. As a portion of all observation visits, there was a 22% drop in the proportion that were observed for chest pain. The daily number of chest pain patients requiring inpatient admission was unchanged. The daily total direct cost for chest pain observation decreased with an effective daily cost savings of $4313 USD (95% CI, $1534-$6998). The total daily number of chest pain observation bed hours also decreased by 41.5 hours (95% CI, 13.4-96.4 hours).</p><p><strong>Conclusions: </strong>Implementation of a hs-cTn chest pain protocol was associated with a significant decrease in the number and proportion of observation visits, a decrease in total daily cost and bed hours used, and no increase in inpatient admissions.</p>","PeriodicalId":35914,"journal":{"name":"Critical Pathways in Cardiology","volume":" ","pages":"e0370"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking the Potential of the HEART Pathway: Predicting MACE and Facilitating Nurse-Physician Collaboration in Chest Pain Unit. 释放 HEART Pathway 的潜力:预测 MACE 并促进胸痛科护士与医生的合作。
Q3 Medicine Pub Date : 2025-03-01 Epub Date: 2025-02-21 DOI: 10.1097/HPC.0000000000000374
Zahra Behpour, Zahra Amirsardari, Haniye Aghakhani, Mohammadesmaeil Zanganehfar, Shiva Khaleghparast, Fidan Shabani, Hooman Bakhshandeh, Parham Sadeghipour

Background and objective: The HEART pathway serves as a tool for predicting major adverse cardiac events (MACE) among patients presenting with acute chest pain, aiding in the early discharge of low-risk patients and reducing unnecessary cardiac investigations. This study aimed to evaluate physician-nurse reliability of the HEART pathway and investigate the efficacy of HEART pathway to predict 3-month MACE in patients with acute chest pain.

Methods: We conducted a prospective study on 97 patients experiencing acute chest pain. A team of 3 professionals, a nurse, a cardiology resident, and a cardiology attending physician, performed risk stratification. We assessed interrater reliability among the raters as well as explored 3-month MACE outcomes.

Results: Excellent pairwise agreements were found between the raters. Overall agreement among raters was excellent, with an intraclass correlation coefficient of 0.84 (95% confidence interval: 0.73-0.97). The HEART pathway score exhibited strong predictive power (area under curve: 0.85) for 3-month MACE. At a cutoff score of 4, sensitivity, specificity, and negative predictive values were 87.5%, 58.9%, and 95.8%, respectively.

Conclusions: The HEART pathway score effectively predicts 3-month MACE in patients with acute nontraumatic chest pain. Moreover, the high agreement among the attending physician, the resident physician, and the nurse suggests that nurses could use this tool, potentially reducing the workload on physicians.

背景和目的:HEART 路径是预测急性胸痛患者主要不良心脏事件 (MACE) 的工具,有助于低风险患者尽早出院并减少不必要的心脏检查。本研究旨在评估 HEART 路径的医生-护士可靠性。此外,还研究了 HEART 路径预测急性胸痛患者 3 个月 MACE 的有效性:我们对 97 名急性胸痛患者进行了前瞻性研究。由一名护士、一名心脏病学住院医师和一名心脏病学主治医师组成的三人专业团队进行了风险分层。我们评估了评分者之间的可靠性,并探讨了 3 个月的 MACE 结果:结果:评分者之间的配对一致性极佳。评分者之间的总体一致性非常好,ICC 为 0.84(95% CI:0.73 - 0.97)。HEART 路径评分对 3 个月的 MACE 具有很强的预测能力(AUC:0.85)。在截断分数为 4 时,灵敏度、特异性和阴性预测值分别为 87.5%、58.9% 和 95.8%:结论:HEART 路径评分可有效预测急性非创伤性胸痛患者 3 个月后的 MACE。此外,主治医生、住院医生和护士之间的高度一致表明护士可以使用这一工具,从而减轻医生的工作量。
{"title":"Unlocking the Potential of the HEART Pathway: Predicting MACE and Facilitating Nurse-Physician Collaboration in Chest Pain Unit.","authors":"Zahra Behpour, Zahra Amirsardari, Haniye Aghakhani, Mohammadesmaeil Zanganehfar, Shiva Khaleghparast, Fidan Shabani, Hooman Bakhshandeh, Parham Sadeghipour","doi":"10.1097/HPC.0000000000000374","DOIUrl":"10.1097/HPC.0000000000000374","url":null,"abstract":"<p><strong>Background and objective: </strong>The HEART pathway serves as a tool for predicting major adverse cardiac events (MACE) among patients presenting with acute chest pain, aiding in the early discharge of low-risk patients and reducing unnecessary cardiac investigations. This study aimed to evaluate physician-nurse reliability of the HEART pathway and investigate the efficacy of HEART pathway to predict 3-month MACE in patients with acute chest pain.</p><p><strong>Methods: </strong>We conducted a prospective study on 97 patients experiencing acute chest pain. A team of 3 professionals, a nurse, a cardiology resident, and a cardiology attending physician, performed risk stratification. We assessed interrater reliability among the raters as well as explored 3-month MACE outcomes.</p><p><strong>Results: </strong>Excellent pairwise agreements were found between the raters. Overall agreement among raters was excellent, with an intraclass correlation coefficient of 0.84 (95% confidence interval: 0.73-0.97). The HEART pathway score exhibited strong predictive power (area under curve: 0.85) for 3-month MACE. At a cutoff score of 4, sensitivity, specificity, and negative predictive values were 87.5%, 58.9%, and 95.8%, respectively.</p><p><strong>Conclusions: </strong>The HEART pathway score effectively predicts 3-month MACE in patients with acute nontraumatic chest pain. Moreover, the high agreement among the attending physician, the resident physician, and the nurse suggests that nurses could use this tool, potentially reducing the workload on physicians.</p>","PeriodicalId":35914,"journal":{"name":"Critical Pathways in Cardiology","volume":" ","pages":"e0374"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141749209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Critical Pathways in Cardiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1